Please login to the form below

Not currently logged in
Email:
Password:

Inviragen

This page shows the latest Inviragen news and features for those working in and with pharma, biotech and healthcare.

Sanofi's dengue vaccine could debut in 2015

Sanofi's dengue vaccine could debut in 2015

Takeda is also developing a vaccine against dengue fever that was acquired along with other candidates when it took over Inviragen last year in a deal valued at up to $250m.

Latest news

  • Takeda buys vaccines specialist Inviragen Takeda buys vaccines specialist Inviragen

    The biopharma company Inviragen, which has operations in the US and Singapore, will receive an upfront payment of $25m, and development and commercial milestones of up to $215m. ... In addition to its dengue vaccine, Takeda will also acquire the rights

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch table for May 2013 Deal Watch table for May 2013

    UAE based regional company $40m $244m option for 52%. 284. Inviragen/ Takeda.

  • Pharma deals during May 2013 Pharma deals during May 2013

    targets from Abide; Takeda's $250m acquisition of Inviragen; GSK's $325m acquisition of the vaccine platform technology company, Okairos; and BMS's $112m licence for antibody conjugates from Ambrx. Note

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics